mRNA Needle Fun Times
Here are snippets from the conclusion & evidence summary of mRNA vax review from the University of Pennsylvania (December 2020):
-no specific guidelines for use of messenger RNA (mRNA) vaccines
-No large trials of any mRNA vaccine have been completed yet
-The only evidence on safety of mRNA vaccines comes from small phase I and phase II trials of SARS-CoV-2 vaccines
-Severe systemic adverse events were reported by 5 to 10 percent of trial subjects
-The rate and severity of adverse events appears to be higher for the second dose of vaccine than for the first
-Higher vaccine doses appear to increase the rate and severity of adverse events
-There is not sufficient evidence to support any conclusions on the comparative safety
-Direct evidence on the comparative safety of mRNA vaccines and other vaccines is lacking
-The current evidence base on messenger RNA (mRNA) vaccines is made up entirely of small early-stage trials
-which examined only short-term outcomes
-They lack sufficient power for testing the statistical significance of most results, and for assessing the risk of serious but uncommon adverse events
-there are a few trends that appear to be consistent across the different studies
-The rate of severe adverse effects (severe enough to interfere with a person’s daily activities) appears to be in the range of 5 to 10 percen
-The rate and severity of adverse events increases with vaccine dos
-The rate and severity of adverse events also appears to be greater following a second dose of vaccine than following the first
http://www.uphs.upenn.edu/cep/COVID/mRNA%20vaccine%20review%20final.pdf